Economy

FDA asked to OK commercial vaccines 

A HEALTH WORKER prepares to administer a coronavirus disease 2019 vaccine at a vaccination facility in Quezon City, June 23, 2021. — PHILIPPINE STAR/ MICHAEL VARCAS

A LAWMAKER has asked the Food and Drug Administration (FDA) to approve the commercial use of various coronavirus vaccines.  

In a statement, Party-list Rep. Edwin L. Gardiola noted that while the palace had extended the state of calamity until year-end, the government should eventually approve the vaccines for commercial use. 

The extension allowed the continued emergency use of the vaccines. 

Mr. Gardiola said the Department of Health and FDA should start acquiring bivalent vaccine boosters as soon as possible.  

“There is no official word yet on how soon we can have these bivalent booster vaccines here in the Philippines,” the congressman said, referring to newer vaccines that offer better protection against more contagious variants. — Matthew Carl L. Montecillo 

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular

Your daily news source covering investing ideas, market stocks, business, retirement tips from Wall St. to Silicon Valley.

Disclaimer:

TheProficientInvestor.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice.
The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 TheProficientInvestor. All Rights Reserved.

To Top